SLC5A7 and cancer: However, this suggests a poor response to ChT in hormone receptor-positive cancers. It was observed that 50% of all cases classified as RCB-I belonged to the basal immunohistochemical subtype, with only 6.4% of this subtype in the RCB-III group.